(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...